Gujarat Kidney and Super Speciality Financial Statements
Gujarat Kidney and Super Speciality financial statements. In FY2026, Gujarat Kidney and Super Speciality (GKSL) reported revenue ₹31 Cr, net profit ₹5 Cr and EPS ₹0.81, with a net profit margin of 16.1% and ROE of 2.0%. Full financial statements from FY2022 to FY2026 (5 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Gujarat Kidney and Super Speci stock price NSE.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
GKSL Revenue, Net Profit & EBITDA — Year-on-Year Growth
GKSL YoY (Mar 2025 vs Mar 2026) — revenue +210.0%, net profit +400.0%, EBITDA +133.3%, expenses +242.9%. Read GKSL dividend track record for the complete payout history and dividend yield track record.
GKSL Income Statement — Revenue, EBITDA & Net Profit
Gujarat Kidney and Super Speciality revenue ₹31 Cr, EBITDA ₹7 Cr, net profit ₹5 Cr, EPS ₹0.81 (2026) — net profit margin 16.1%. Analyse GKSL FII DII holdings to track promoter, FII and institutional holdings.
| Particulars | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 31 | 35 | 13 | 10 | 15 | 23 | 9 | 12 |
| Expenses | 24 | 26 | 8 | 7 | 7 | 16 | 5 | 7 |
| EBITDA | 7 | 9 | 5 | 3 | 9 | 7 | 5 | 5 |
| Operating Profit Margin % | 21.00% | 24.00% | 40.00% | 27.00% | 57.00% | 30.00% | 52.00% | 39.00% |
| Depreciation | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit Before Tax | 5 | 7 | 4 | 2 | 8 | 5 | 4 | 4 |
| Tax | 0 | 2 | 1 | 0 | 2 | 1 | 1 | 1 |
| Net Profit | 5 | 5 | 3 | 1 | 5 | 4 | 3 | 3 |
| Earnings Per Share (₹) | 0.81 | 0.66 | 0.47 | 0.25 | 0.85 | 0.52 | 0.65 | 0.52 |
GKSL Balance Sheet — Assets, Liabilities & Shareholders' Equity
GKSL total assets ₹298 Cr, total equity ₹255 Cr, total liabilities ₹ Cr (2026) — ROE 2.0%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Total Assets | 298 | 55 | 21 | 4 | 4 |
| Current Assets | 105 | 22 | 7 | 1 | 1 |
| Fixed Assets | 129 | 31 | 14 | 0 | 3 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 |
| Investments | 12 | 0 | 0 | 0 | 0 |
| Other Assets | 157 | 24 | 7 | 4 | 1 |
| LIABILITIES | |||||
| Total Liabilities | |||||
| Current Liabilities | 15 | 7 | 6 | 0 | 0 |
| Non-Current Liabilities | |||||
| SHAREHOLDERS' EQUITY | |||||
| Total Equity | 255 | 27 | 11 | 0 | 0 |
| Share Capital | 16 | 11 | 0 | 0 | 0 |
| Reserves & Surplus | 237 | 15 | 2 | 0 | 0 |
GKSL Cash Flow Statement — Operating, Investing & Financing
Gujarat Kidney and Super Speciality operating cash flow ₹-4 Cr, investing ₹-214 Cr, financing ₹228 Cr, net cash flow ₹11 Cr (2026).
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 |
|---|---|---|---|---|
| Operating Activities | -4 | 14 | 1 | 0 |
| Investing Activities | -214 | -18 | 0 | 0 |
| Financing Activities | 228 | 6 | -1 | 0 |
| Net Cash Flow | 11 | 2 | 1 | 0 |